You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tumor- infiltrating immune cells

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Glioblastoma Multiforme Trial in Shanghai (TIL, PD1-TIL)

Active, not recruiting
  • Glioblastoma Multiforme
  • Shanghai, Shanghai, China
    Huashan hospital, Fudan University
Aug 24, 2021

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 Trial in Houston

Active, not recruiting
  • Metastatic Melanoma
  • +2 more
  • Aldesleukin
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Carcinoma, Melanoma, Bladder Cancer Trial in Chengdu (Tumor antigen-sensitized DC vaccine and their sensitized T cells

Not yet recruiting
  • Carcinoma
  • +3 more
  • Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration
  • Chengdu, Sichuan, China
    West China Hospital
Feb 10, 2022

Tumor Budding in Colorectal Cancer Under Different MMR Status

Completed
  • Tumor Budding
  • Rectal Cancer
  • total mesorectal exicision
  • Guangzhou, Guangdong, China
    Department of colorectal surgery, the Sixth Affiliated Hospital,
Nov 8, 2022

Advanced Breast Adenocarcinoma, Advanced HER2-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8 Trial (Best

Withdrawn
  • Advanced Breast Adenocarcinoma
  • +14 more
  • Best Practice
  • +3 more
  • (no location specified)
Jun 7, 2022

Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma Trial in Bethesda, Seattle, Madison (Cyclophosphamide,

Recruiting
  • Recurrent Neuroblastoma
  • +3 more
  • Palo Alto, California
  • +3 more
Jan 25, 2023

Non Small Cell Lung Cancer Trial in Durham (Ipilimumab, Paclitaxel, Cisplatin, Carboplatin)

Completed
Has Results
  • Non Small Cell Lung Cancer
  • Durham, North Carolina
    Duke University Medical Center
Feb 24, 2021

Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Durvalumab
  • Rintatolimod
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC
Jun 23, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Los

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +5 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +3 more
  • Los Angeles, California
    USC/Norris Comprehensive Cancer Center
Jan 31, 2023

NSCLC, Metastatic Non Small Cell Lung Cancer, Stage IV NSCLC Trial in Duarte, Minneapolis (Fludarabine, Cyclophosphamide, CISH

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +5 more
  • Duarte, California
  • +1 more
Dec 7, 2022

Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant Trial in Jyväskylä, Oulu, New Delhi (EGFRvIII-specific hinge-optimized

Active, not recruiting
  • Glioblastoma
  • +2 more
  • EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes
  • Jyväskylä, Finland
  • +2 more
Sep 30, 2021

Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma Trial in Tampa (TBio-4101, Cyclophosphamide, Fludarabine)

Recruiting
  • Metastatic Melanoma
  • +9 more
  • TBio-4101
  • +3 more
  • Tampa, Florida
    Moffitt Cancer Center
Jan 24, 2023

Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer, Peritoneal Cancer Trial in Herlev (Ipilimumab, Cyclophosphamid,

Recruiting
  • Metastatic Ovarian Cancer
  • +2 more
  • Herlev, Denmark
    National Center for Cancer Immune Therapy (CCIT-DK)
May 7, 2021

Advanced Solid Tumor Trial in Taoyuan (Neoantigen-expanded cell therapy.)

Recruiting
  • Advanced Solid Tumor
  • Neoantigen-expanded cell therapy.
  • Taoyuan, Taiwan
    Chang Gung Memorial Hospital, Linkou
Aug 18, 2021

Metastatic Melanoma Trial in Copenhagen, Nantes (TILT-123)

Recruiting
  • Metastatic Melanoma
  • TILT-123
  • Copenhagen, Denmark
  • +1 more
Dec 17, 2021

Metastatic Melanoma Trial run by the National Cancer Institute (NCI) (Aldesleukin, Fludarabine, Cyclophosphamide)

Completed
Has Results
  • Metastatic Melanoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 21, 2022

Squamous Cell Carcinoma of Head and Neck Trial in Essen (Atezolizumab)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Essen, Germany
    University Hospital Essen
Nov 2, 2022

Detect and Expunge Concealed Tumors of the Liver

Recruiting
  • Liver Cancer
    • Hanoi, Vietnam
      108 Military Central Hospital
    Nov 15, 2023

    Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer Trial in San Francisco, Saint Louis (Atezolizumab,

    Recruiting
    • Prostate Adenocarcinoma
    • +2 more
    • San Francisco, California
    • +1 more
    Oct 8, 2022

    Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone Trial in Houston (biological, drug, other)

    Recruiting
    • Bone Sarcoma
    • +15 more
    • Aldesleukin
    • +8 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 3, 2022

    Breast Cancer Trial in Ansan (MRI)

    Completed
    • Breast Cancer
    • MRI
    • Ansan, Korea, Republic of
      Bo Kyoung Seo
    Oct 18, 2023

    The Status of Immune Checkpoints at Gastrointestinal Cancer

    Completed
    • Gastrointestinal Cancer
    • Flow cytometric analysis
    • Istanbul, Turkey
      Istanbul Training and Reseach Hospital
    Dec 4, 2022

    Triple Negative Breast Cancer Trial (Cryoablation, Cryoablation combined with PD1 Inhibitor)

    Not yet recruiting
    • Triple Negative Breast Cancer
    • Cryoablation
    • Cryoablation combined with PD1 Inhibitor
    • (no location specified)
    Mar 28, 2023

    Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial (biological, procedure, drug)

    Not yet recruiting
    • Advanced Malignant Solid Neoplasm
    • Refractory Malignant Solid Neoplasm
    • Atezolizumab
    • +5 more
    • (no location specified)
    Feb 4, 2023

    Stage IIIB(N2) NSCLC, Stage IIA NSCLC, Stage IIB NSCLC Trial in Beijing (Pembrolizumab 200 mg IV infusion)

    Not yet recruiting
    • Stage IIIB(N2) Non-small Cell Lung Cancer
    • +3 more
    • Pembrolizumab 200 mg IV infusion
    • Beijing, Beijing, China
      Peking University
    May 30, 2023